ロード中...
Trametinib: A Targeted Therapy in Metastatic Melanoma
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progression-free survival and overall survival advantage compared to chemotherapy....
保存先:
| 出版年: | J Adv Pract Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Harborside Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570520/ https://ncbi.nlm.nih.gov/pubmed/31249721 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|